. Author manuscript; available in PMC: 2022 Jul 1.

Published in final edited form as: Mult Scler. 2022 Jan 7;28(8):1277–1285. doi: 10.1177/13524585211061861

Table 2.

Hazard ratios (HR) of conversion to CDMS/MDMS^a by BMI categories and smoking status


	CDMS^a			2001 MDMS^b
	No. y/n	HR	95% CI	No. y/n	HR	95% CI
BMI (kg/m²)
All
<18.5	8/10	1.27	0.61–2.63	14/4	1.07	0.65–1.76
18.5–<25	129/142	1	Ref.	224/47	1	Ref.
25–<30	54/65	1.10	0.79–1.54	94/25	1.11	0.88–1.39
>30	25/32	1.00	0.62–1.59	45/12	1.39	1.02–1.91
Non-smokers
<18.5	5/5	1.47	0.57–3.82	8/2	1.02	0.50–2.08
18.5–<25	70/82	1	Ref.	125/27	1	Ref.
25–<30	27/36	0.98	0.62–1.56	48/15	1.02	0.75–1.40
>30	16/17	1.07	0.58–1.97	28/57	1.65	1.08–2.50
Active smokers
<18.5	2/4	0.78	0.17–3.55	5/1	1.27	0.51–3.13
18.5–<25	41/46	1	Ref.	72/15	1	Ref.
25–<30	17/22	1.00	0.54–1.87	32/7	1.06	0.68–1.64
>30	8/12	1.05	0.45–2.48	13/7	0.84	0.47–1.51

Models adjusted for age, sex, treatment allocation, and baseline: serum 25(OH) vitamin D with seasonal correction, no. T2 lesions, T2 lesion volume, EDSS score, steroid treatment, EBNA-1 IgG levels, smoking status.

CDMS: Clinically Definite Multiple Sclerosis.

2001 McDonald MS